Search research articles
Contact Us
Filters
Showing results (51-60 of 118) with videos related to
Page
of 12
Sort By:
Journal of Thoracic Disease
|
November 12, 2015
Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis
Wen-Zhao Zhong, Wei Li, Xue-Ning Yang, et al.
Clinical and Translational Medicine
|
June 9, 2020
Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism
Si-Yang Liu, Jia-Ying Zhou, Wen-Feng Li, et al.
The International Journal of Biological Markers
|
December 23, 2015
Polymorphism of rs9387478 correlates with overall survival in female nonsmoking patients with lung cancer
Jie-Fei Han, She-Juan An, Wen-Mei Su, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2019
A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)
Zhen Wang, Cheng Huang, Jin-Ji Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 4, 2017
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
E-E Ke, Qing Zhou, Qiu-Yi Zhang, et al.
Therapeutic Advances in Medical Oncology
|
February 9, 2024
Plasma ddPCR for the detection of <i>MET</i> amplification in advanced NSCLC patients: a comparative real-world study
Jun-Wei Su, Cheng-Di Weng, Xiao-Cheng Lin, et al.
The Oncologist
|
September 17, 2014
Lung cancer treatment disparities in China: a question in need of an answer
Lu-Lu Yang, Xu-Chao Zhang, Xue-Ning Yang, et al.
Plos One
|
July 7, 2012
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status
She-Juan An, Zhi-Hong Chen, Jian Su, et al.
Journal for Immunotherapy of Cancer
|
July 18, 2023
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
Jia-Yi Deng, Qing Gou, Lingling Yang, et al.
Clinical Lung Cancer
|
June 20, 2025
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)
Jia-Xin Lin, Qing Zhou, Hong-Hong Yan, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 118) with videos related to
Sort By:
Page
of 12
Journal of Thoracic Disease
|
November 12, 2015
Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis
Wen-Zhao Zhong, Wei Li, Xue-Ning Yang, et al.
Clinical and Translational Medicine
|
June 9, 2020
Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism
Si-Yang Liu, Jia-Ying Zhou, Wen-Feng Li, et al.
The International Journal of Biological Markers
|
December 23, 2015
Polymorphism of rs9387478 correlates with overall survival in female nonsmoking patients with lung cancer
Jie-Fei Han, She-Juan An, Wen-Mei Su, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2019
A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002)
Zhen Wang, Cheng Huang, Jin-Ji Yang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 4, 2017
A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R
E-E Ke, Qing Zhou, Qiu-Yi Zhang, et al.
Therapeutic Advances in Medical Oncology
|
February 9, 2024
Plasma ddPCR for the detection of <i>MET</i> amplification in advanced NSCLC patients: a comparative real-world study
Jun-Wei Su, Cheng-Di Weng, Xiao-Cheng Lin, et al.
The Oncologist
|
September 17, 2014
Lung cancer treatment disparities in China: a question in need of an answer
Lu-Lu Yang, Xu-Chao Zhang, Xue-Ning Yang, et al.
Plos One
|
July 7, 2012
Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status
She-Juan An, Zhi-Hong Chen, Jian Su, et al.
Journal for Immunotherapy of Cancer
|
July 18, 2023
Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer
Jia-Yi Deng, Qing Gou, Lingling Yang, et al.
Clinical Lung Cancer
|
June 20, 2025
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)
Jia-Xin Lin, Qing Zhou, Hong-Hong Yan, et al.
Page
of 12